[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adolescents-with-obesity-or-overweight-with-weight-related-comorbidities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adolescents-with-obesity-or-overweight-with-weight-related-comorbidities":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100612563","phase-3-a-study-of-ibi362-in-chinese-adolescents-with-obesity-or-overweight-100612563",false,"NCT07255209","A Study of IBI362 in Chinese Adolescents With Obesity or Overweight","A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）","Inclusion Criteria:\n\nParticipants must meet all of the following inclusion criteria to be enrolled:\n\nKey Inclusion Criteria：\n\n1. Male or female participants aged ≥12 years and \\\u003C18 years at the time of signing the informed consent\u002Fassent form.\n2. BMI at screening meeting the obesity criteria defined by \"WS\u002FT 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents\" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome.\n3. Weight change \\\u003C5 kg after ≥12 weeks of diet and exercise alone before screening (per self\u002Fparental report).\n\nExclusion Criteria:\n\nKey Exclusion Criteria：\n\n1. Prior diagnosis of type 1 diabetes.\n2. Pre-pubertal participants (Tanner Stage I).\n3. History of (or planned) bariatric surgery (except liposuction\u002Fabdominoplasty or acupuncture for weight loss performed \\>1 year before screening).","ALL","12 Years","18 Years",{"count":20,"type":21},180,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \\\u003C18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.",[27],"Adolescents With Obesity or Overweight With Weight-Related Comorbidities","RECRUITING","2026-01-07",{"date":31,"type":32},"2026-01-08","ACTUAL",{"date":34,"type":32},"2025-12-29",{"date":36,"type":21},"2028-10-31",{"name":38,"class":39},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY"]